Table 4 Brazil SUS Incorporations and PCDTs – National Committee for Technology Incorporation (CONITEC) Recommendations 2016–2019
From: A civil society view of rare disease public policy in six Latin American countries
Year | Treatment | Rare Disease | Decision | Date |
|---|---|---|---|---|
2016 [32] | – | – | – | – |
– | Tobramycin | Cystic Fibrosis | Incorporate | 10/27/2016 |
– | Golimumab | Psoriatic Arthritis | Incorporate | 4/12/2016 |
– | Pancrelipase | Cystic Fibrosis | Exclude | 1/18/2016 |
2017 [33] | – | – | – | – |
– | Idursulfase | MPS II | Incorporate | 12/20/2017 |
– | Somatropin | Turner Syndrome and Hypopituitarism | Incorporate | 11/3/2017 |
– | Laronidase | MPS I | Incorporate | 9/4/2017 |
– | PCDT | Cystic Fibrosis (Pancreatic Insufficiency) | Approve | 9/4/2017 |
– | PCDT | Cystic Fibrosis (Pulmonary) | Approve | 9/4/2017 |
– | Alfataliglicerase | Gaucher Disease | Increase use | 7/12/2017 |
– | PCDT | Psoriatic Arthritis | Approve | 7/19/2017 |
– | PCDT | Gaucher Disease | Approve | 6/27/2017 |
2018 [34] | – | – | – | – |
– | Pirfenidone | Idiopathic Pulmonary Fibrosis | Not Incorporate | 12/26/2018 |
– | Nintedanib | Idiopathic Pulmonary Fibrosis | Not Incorporate | 12/26/2018 |
– | Zoledronic Acid | Paget’s Disease | Incorporate | 12/21/2018 |
– | Galsulfase | MPS VI | Incorporate | 12/20/2018 |
– | Elosulfase Alfa | MPS IVa | Incorporate | 12/20/2018 |
– | Sapropterin | Phenylketonuria | Incorporate | 12/17/2018 |
– | Eculizumab | Paroxistic Nocturnal Hemoglobinuria | Incorporate | 12/17/2018 |
– | Agalsidase (Alfa and Beta) | Fabry’s Disease | Not Incorporate | 12/17/2018 |
– | Eltrombopag Olamine | Idiopathic Thrombocytopenic Purpura | Incorporate | 12/12/2018 |
– | Romiplostim | Idiopathic Thrombocytopenic Purpura | Not Incorporate | 12/12/2018 |
– | PCDT | Autoimmne Hemolytic Anemia | Approve | 12/10/2018 |
– | PCDT | Psoriatic Arthritis | Approve | 11/5/2018 |
– | PCDT | Familial Amyloid Polyneuropathy | Approve | 10/10/2018 |
– | PCDT | MPS II | Approve | 5/25/2018 |
– | PCDT | Turner Syndrome | Approve | 5/24/2018 |
– | PCDT | Autoimmune Hepatitis | Approve | 5/24/2018 |
– | PCDT | Biotinidase Deficiency | Approve | 5/24/2018 |
– | PCDT | MPS I | Approve | 4/18/2018 |
– | PCDT | Wilson Disease | Approve | 4/9/2018 |
– | PCDT | Sickle Cell Disease | Approve | 2/22/2018 |
– | Certolizumab | Psoriatic Arthritis | Not Incorporate | 1/25/2018 |
– | Ustekinumab | Psoriatic Arthritis | Not Incorporate | 1/25/2018 |
– | Tafamidis | Familial Amyloid Polyneuropathy | Incorporate | 1/18/2018 |
2019 (Up to 4/1/19) [35] | – | – | – | – |
– | Eftrenonacog Alfa | Hemophilia B | Not Incorporate | 2/22/2019 |
– | Efmoroctocog Alfa | Hemophilia A | Not Incorporate | 2/22/2019 |
– | Secukinumab | Psoriatic Arthritis | Incorporate | 1/21/2019 |
– | PCDT | Acromegaly | Approve | 1/14/2019 |